Protocol Number; CRTH258A1401

A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031200370

Enrollment

300

Registered

2021-02-19

Start date

2020-11-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients must provide written consent to cooperate in this study before treatment with Beovu kit for intravitreal injection 2. Patients using Beovu kit for intravitreal injection for the first time for the following indication: Indication: age-related macular degeneration with subfoveal choroidal neovascularization

Exclusion criteria

Exclusion criteria: Patients with a history of treatment with a drug containing the same ingredient (brolucizumab; investigational drug or post-marketing clinical study drug) as Beovu kit for intravitreal injection

Design outcomes

Primary

Measure	Time frame
1. Number of patients with adverse events in the eyes [ Time Frame: 52 weeks ] 2. Number of patients with adverse events in other parts of the body (non-ocular) [ Time Frame: 52 weeks]	—

Contacts

Public ContactNovartis Direct -

Novartis Pharma. K.K.

sm.pms@novartis.com+81-120003293

Outcome results